Pediatric Hematologist/Oncologist (Child Cancer Specialist)
Joanne Lagmay, M.D., is board-certified in general pediatrics and pediatric hematology/oncology. Her main focus has been the multidisciplinary treatment of pediatric solid tumors, specifically pediatric sarcoma of the bone and soft tissue. She also has special interest in pediatric palliative care. Dr. Lagmay participates in several national professional societies and committees, including the Children’s Oncology Group, American Society of Pediatric Hematology and Oncology, American Society of Hematology, Connective Tissue Oncologic Society, and STOP Children’s Cancer. Her practice integrates translational research in targeted radionuclide therapies for osteosarcoma in collaboration with UF Veterinary Medicine, Biomedical Engineering, Chemistry, Material Science Engineering and Radiation Oncology. Her direct collaboration with pediatric oncology colleagues in Florida has resulting phase I clinical trials for pediatric cancer patients in the state. Dr. Lagmay came to UF in 2009 from Nationwide Children’s Hospital, The Ohio State University where she was a fellow in pediatric hematology/oncology. She did her pediatric residency training at the Children’s Hospital of Monmouth in New Jersey, where she also served as chief resident.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesThis single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to…
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food & Drug…
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles…
September 12, 2024
GAINESVILLE, Fla. — Eight years ago, Jennifer Arrington was simultaneously planning her unborn son’s funeral and her own. Diagnosed with a rare pediatric…
College of Medicine, UF Health Cancer Institute, +2 more
